Enclomiphene vs MENT
Well Studied vs Emerging
synergistic Mechanism-based · 46% MENT supports hormonal recovery from suppression caused by Enclomiphene. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Enclomiphene MENT
Weight 405.96 Da 288.43 Da
Half-life ~10 hours ~40 minutes (acetate ester)
Type Trans-isomer of clomifene (selective estrogen receptor modulator) 7-alpha-methyl-19-nortestosterone (C19H28O2)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
MENT
01 Approximately 10x more potent than testosterone, allowing effective results at very low doses (5-25 mg/day)
02 Does not cause the sexual dysfunction associated with other 19-nor compounds like nandrolone
03 Can potentially serve as a standalone base, replacing testosterone in hormone replacement protocols
04 Rapid clearance of the acetate ester allows quick dose adjustments and fast resolution of side effects upon discontinuation
05 Powerful lean mass accretion and strength gains relative to dose
06 Under investigation as a reversible male hormonal contraceptive
07 Resistance to 5-alpha reductase means it does not convert to DHT, potentially sparing hair follicles from direct DHT-mediated damage
08 Robust suppression of gonadotropins (LH/FSH), which is therapeutically useful in contraceptive applications
Dosing Protocols
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
MENT
5-25 mg/day (acetate) / Daily or split into 2x daily (acetate ester)
TRT Replacement - Low Dose 5-10 mg/day Daily (or split into 2 injections per day)
Moderate Anabolic Protocol 10-15 mg/day Split into 2 injections per day
Higher Dose - Advanced 15-25 mg/day Split into 2 injections per day
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
MENT
Estrogen management difficulty -- 7-alpha-methyl-estradiol is harder to control with conventional aromatase inhibitors
Water retention and bloating, particularly at doses above 10 mg/day
Elevated blood pressure, often linked to water retention and estrogenic load
Mood changes including irritability, emotional sensitivity, or anxiety (frequently estrogen-related)
Profoundly suppressive of the HPG axis -- LH and FSH driven to near-zero even at low doses
Injection frequency burden (daily or twice-daily with acetate ester)
Mild acne and oily skin
Increased appetite
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy
Severe hepatic impairment
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled hypertension or severe cardiovascular disease
Uncontrolled heart failure
Known hypersensitivity to trestolone or any formulation components
Research Evidence
Enclomiphene MENT
Status Well Studied Emerging
References 5 studies 5 studies
Latest — 2002
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.